SECURITIES AND EXCHANGE COMMISSION

                           Washington, D. C.  20549

                                   FORM 8-K
                         
                                CURRENT REPORT

                      Pursuant to Section 13 or 15(d) of
                      the Securities Exchange Act of 1934

                       Date of Report:  July 1, 1997



                         Seafield Capital Corporation             
            ------------------------------------------------------
            (Exact name of registrant as specified in its charter)

       Missouri                   0-16946                   43-1039532
     --------------------------------------------------------------------
     (State of other     (Commission File Number)        (IRS Employer
     jurisdiction of                                    Identification
     incorporation)                                         Number)


     5000 W. 95th Street, Suite 260
     P. O. Box 7568
     Shawnee Mission, KS                                     66207 
     --------------------------------------------------------------------
     (Address of principal executive offices)              (Zip code)


                               (913)  652-1000           
     --------------------------------------------------------------------
            (Registrant's telephone number, including area code)


     2600 Grand Blvd., Suite 500  P.O. Box 410949  Kansas City, MO  64141
     --------------------------------------------------------------------
                       (Registrant's former address)





Item 5.  Other Events

On July 1, 1997, the Registrant issued the following news release:

"Seafield Capital Corporation (Seafield) announced today that the Seafield 
Board of Directors has declared a dividend to its shareholders of record on 
July 11, 1997 of all shares of common stock of Response Oncology, Inc. 
(Response) owned by Seafield (i.e., 8,077,392 shares).  Approximately 1.24 
shares of Response common stock will be distributed for each share of 
Seafield common stock outstanding.  Share certificates will be mailed on or 
about July 25, 1997.

The effective ex-dividend date established by the NASD for the distribution 
is July 28, 1997.  Sales of Seafield stock with trading dates of July 9 
through July 25 will have "due bills" attached to the sales.  Sellers 
during this period will therefore be required to forward Response stock to 
the purchaser when received.

The Seafield Board believes that the separation of Seafield's ownership 
interest in Response from Seafield's core laboratory testing business will 
provide investors a sharper focus as to the particular merits of each of 
those investments and therefore provide Seafield shareholders with a better 
recognition of the value of each of those investments.

The Securities and Exchange Commission today declared effective the 
Registration Statement of Response, thereby enabling the distribution to 
proceed.

Response common stock is traded on the NASDAQ national market under the 
symbol "ROIX".  The closing price of Response common stock, as reported on 
NASDAQ on June 30, 1997 was $7.375 per share.

The Distribution is being made only by means of a Prospectus.  The 
Prospectus contains information regarding Response and the proposed 
distribution.  Copies of the Prospectus may be obtained from Seafield at 
5000 W. 95th Street, Suite 260, Post Office Box 7568, Shawnee Mission, 
Kansas 66207 or from Response at 1775 Moriah Woods Boulevard, Memphis, 
Tennessee 38117.

THIS COMMUNICATION SHALL NOT CONSTITUTE A OFFER TO SELL OR THE SOLICITATION 
OF AN OFFER TO BUY ANY SHARES OF RESPONSE ONOCLOGY, INC. COMMON STOCK BEING 
DISTRIBUTED.

On July 1, 1997,  the Board of Directors of Seafield declared a regular 
quarterly cash dividend of 30 cents per share, payable September 3, 1997 to 
shareholders of record August 26, 1997."



On July 1, 1997, the Registrant issued the following news release:

"Seafield Capital Corporation (Seafield) announced today that discussions 
between Seafield and its 82%-owned subsidiary, LabOne, Inc., regarding a 
possible merger between the two companies have been terminated.  In 
February 1995, Seafield had announced that among the strategic alternatives 
which Seafield expected to pursue was a merger of Seafield into LabOne.  
Following the transfer of many of Seafield's assets to SLH Corporation and 
the distribution of all SLH Corporation stock to Seafield's shareholders 
earlier this year, Seafield and LabOne began discussing a possible merger.  
It was also contemplated at the time initial merger discussions began that 
Seafield would distribute its Response Oncology holdings to shareholders.  
Such distribution is now expected to be effected in late July. 

Following the distribution of SLH and Response shares to Seafield 
shareholders, the remaining Seafield assets will consist only of 
approximately $5 million in cash and 10,712,200 LabOne shares.  

As the merger discussions proceeded, Seafield and LabOne were advised that 
any combination of the two companies would result in the surviving entity 
having a significant amount of additional annual amortization expense.  
Seafield has concluded that the benefits of combining the two companies at 
this time do not justify the additional amortization and the resulting 
adverse impact on earnings.  Accordingly, merger discussions between 
Seafield and LabOne have been terminated.

In light of this development and the expected distribution to Seafield's 
shareholders of all shares of Response Oncology, Inc. common stock owned by 
Seafield, Seafield intends to promptly determine an appropriate corporate 
and expense structure, given that virtually all of its assets will consist 
of its LabOne stock ownership.

LabOne operates a centralized laboratory in the Kansas City area which 
markets clinical, substance abuse and insurance laboratory testing services 
in the United States and Canada.  The common stock of LabOne is traded on 
the National Market System of the Nasdaq Stock Market under the symbol 
"LABS."



                                  SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
     Registrant has duly caused this report to be signed on its behalf by the
     undersigned hereunto duly authorized officer.


                                           Seafield Capital Corporation



     Date:  July 7, 1997                   By: /s/ Steven K. Fitzwater 
                                               ---------------------------
                                               Steven K. Fitzwater
                                               Vice President, Chief Accounting
                                               Officer and Secretary
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 6841}]
{"company-data": {"conformed-name": "SEAFIELD CAPITAL CORP", "cik": "0000830158", "assigned-sic": "8071", "irs-number": "431039532", "state-of-incorporation": "MO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-16946", "film-number": "97637127"}, "business-address": {"street1": "5000 W 95TH STREET SUITE 260", "street2": "P O BOX 7568", "city": "SHAWNEE MISSION", "state": "KS", "zip": "66207", "phone": "9136521000"}, "mail-address": {"street1": "5000 W 95TH STREET SUITE 260", "street2": "P O BOX 7568", "city": "SHAWNEE MISSION", "state": "KS", "zip": "66207"}, "former-company": [{"former-conformed-name": "BMA CORP /MO/", "date-changed": "19910520"}, {"former-conformed-name": "SEAFIELD CAPTIAL CORP", "date-changed": "19910520"}, {"former-conformed-name": "BMA PROPERTIES INC", "date-changed": "19880411"}]}
SECURITIES AND EXCHANGE COMMISSION

                           Washington, D. C.  20549

                                   FORM 8-K
                         
                                CURRENT REPORT

                      Pursuant to Section 13 or 15(d) of
                      the Securities Exchange Act of 1934

                       Date of Report:  July 1, 1997

                         Seafield Capital Corporation             
            ------------------------------------------------------
            (Exact name of registrant as specified in its charter)

       Missouri                   0-16946                   43-1039532
     --------------------------------------------------------------------
     (State of other     (Commission File Number)        (IRS Employer
     jurisdiction of                                    Identification
     incorporation)                                         Number)

     5000 W. 95th Street, Suite 260
     P. O. Box 7568
     Shawnee Mission, KS                                     66207 
     --------------------------------------------------------------------
     (Address of principal executive offices)              (Zip code)

                               (913)  652-1000           
     --------------------------------------------------------------------
            (Registrant's telephone number, including area code)

     2600 Grand Blvd., Suite 500  P.O. Box 410949  Kansas City, MO  64141
     --------------------------------------------------------------------
                       (Registrant's former address)

Item 5.  Other Events

On July 1, 1997, the Registrant issued the following news release:

"Seafield Capital Corporation (Seafield) announced today that the Seafield 
Board of Directors has declared a dividend to its shareholders of record on 
July 11, 1997 of all shares of common stock of Response Oncology, Inc. 
(Response) owned by Seafield (i.e., 8,077,392 shares).  Approximately 1.24 
shares of Response common stock will be distributed for each share of 
Seafield common stock outstanding.  Share certificates will be mailed on or 
about July 25, 1997.

The effective ex-dividend date established by the NASD for the distribution 
is July 28, 1997.  Sales of Seafield stock with trading dates of July 9 
through July 25 will have "due bills" attached to the sales.  Sellers 
during this period will therefore be required to forward Response stock to 
the purchaser when received.

The Seafield Board believes that the separation of Seafield's ownership 
interest in Response from Seafield's core laboratory testing business will 
provide investors a sharper focus as to the particular merits of each of 
those investments and therefore provide Seafield shareholders with a better 
recognition of the value of each of those investments.

The Securities and Exchange Commission today declared effective the 
Registration Statement of Response, thereby enabling the distribution to 
proceed.

Response common stock is traded on the NASDAQ national market under the 
symbol "ROIX".  The closing price of Response common stock, as reported on 
NASDAQ on June 30, 1997 was $7.375 per share.

The Distribution is being made only by means of a Prospectus.  The 
Prospectus contains information regarding Response and the proposed 
distribution.  Copies of the Prospectus may be obtained from Seafield at 
5000 W. 95th Street, Suite 260, Post Office Box 7568, Shawnee Mission, 
Kansas 66207 or from Response at 1775 Moriah Woods Boulevard, Memphis, 
Tennessee 38117.

THIS COMMUNICATION SHALL NOT CONSTITUTE A OFFER TO SELL OR THE SOLICITATION 
OF AN OFFER TO BUY ANY SHARES OF RESPONSE ONOCLOGY, INC. COMMON STOCK BEING 
DISTRIBUTED.

On July 1, 1997,  the Board of Directors of Seafield declared a regular 
quarterly cash dividend of 30 cents per share, payable September 3, 1997 to 
shareholders of record August 26, 1997."

On July 1, 1997, the Registrant issued the following news release:

"Seafield Capital Corporation (Seafield) announced today that discussions 
between Seafield and its 82%-owned subsidiary, LabOne, Inc., regarding a 
possible merger between the two companies have been terminated.  In 
February 1995, Seafield had announced that among the strategic alternatives 
which Seafield expected to pursue was a merger of Seafield into LabOne.  
Following the transfer of many of Seafield's assets to SLH Corporation and 
the distribution of all SLH Corporation stock to Seafield's shareholders 
earlier this year, Seafield and LabOne began discussing a possible merger.  
It was also contemplated at the time initial merger discussions began that 
Seafield would distribute its Response Oncology holdings to shareholders.  
Such distribution is now expected to be effected in late July. 

Following the distribution of SLH and Response shares to Seafield 
shareholders, the remaining Seafield assets will consist only of 
approximately $5 million in cash and 10,712,200 LabOne shares.  

As the merger discussions proceeded, Seafield and LabOne were advised that 
any combination of the two companies would result in the surviving entity 
having a significant amount of additional annual amortization expense.  
Seafield has concluded that the benefits of combining the two companies at 
this time do not justify the additional amortization and the resulting 
adverse impact on earnings.  Accordingly, merger discussions between 
Seafield and LabOne have been terminated.

In light of this development and the expected distribution to Seafield's 
shareholders of all shares of Response Oncology, Inc. common stock owned by 
Seafield, Seafield intends to promptly determine an appropriate corporate 
and expense structure, given that virtually all of its assets will consist 
of its LabOne stock ownership.

LabOne operates a centralized laboratory in the Kansas City area which 
markets clinical, substance abuse and insurance laboratory testing services 
in the United States and Canada.  The common stock of LabOne is traded on 
the National Market System of the Nasdaq Stock Market under the symbol 
"LABS."

                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
     Registrant has duly caused this report to be signed on its behalf by the
     undersigned hereunto duly authorized officer.

                                           Seafield Capital Corporation

     Date:  July 7, 1997                   By: /s/ Steven K. Fitzwater 
                                               ---------------------------
                                               Steven K. Fitzwater
                                               Vice President, Chief Accounting
                                               Officer and Secretary